NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE58376 Query DataSets for GSE58376
Status Public on Mar 16, 2015
Title SMO variants explain the majority of drug resistance in basal cell carcinoma [Target Sequencing]
Organism Homo sapiens
Experiment type Other
Summary Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms, providing a unique opportunity to study human tumor evolution. Here, we identify SMO mutations in 50% (22/44) of resistant BCCs compared with 5.6% (2/36) of untreated BCCs (p<0.0001), and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand binding pocket (LBP) mutations that define sites of inhibitor binding and four variants that confer constitutive activity and inhibitor resistance, thus defining pivotal residues of SMO that ensure receptor autoinhibition. Finally, we show that both classes of SMO variants respond to the aPKC-ι/λ inhibitor PSI and GLI2 antagonist ATO that operate downstream of SMO
 
Overall design Identification of Smo mutations in 30 resistant basal cell cancers and 36 untreated basal cell cancers 
The exonic regions of PTCH1 and SMO were amplified using the Access Array platform (Fluidigm)
 
Contributor(s) Atwood SX, Sarin KY, Li J, Kim G, Rezaee M, Ally MS, Kim J, Yao C, Whitson RJ, Chang AS, Oro AE, Tang JY
Citation(s) 25759020
Submission date Jun 10, 2014
Last update date May 15, 2019
Contact name Jiang Li
E-mail(s) jiangli@stanford.edu
Phone 6507258839
Organization name Stanford University
Department Dermatology
Lab Tony Oro
Street address 269 Campus Drive, Stanford University
City Stanford
State/province CA
ZIP/Postal code 94305
Country USA
 
Platforms (1)
GPL15520 Illumina MiSeq (Homo sapiens)
Samples (66)
GSM1409355 TargetSeq-Resistance1
GSM1409356 TargetSeq-Resistance2
GSM1409357 TargetSeq-Resistance3
This SubSeries is part of SuperSeries:
GSE58377 SMO variants explain the majority of drug resistance in basal cell carcinoma
Relations
BioProject PRJNA252375
SRA SRP043088

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE58376_TargetResequencing_Variants_Matrix.xlsx.gz 11.9 Kb (ftp)(http) XLSX
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap